ID   SNU-739
AC   CVCL_5088
SY   SNU739
DR   cancercelllines; CVCL_5088
DR   Cell_Model_Passport; SIDM01438
DR   DepMap; ACH-002523
DR   GEO; GSM1374898
DR   GEO; GSM2551591
DR   IARC_TP53; 6311
DR   KCLB; 00739
DR   LIMORE; SNU739
DR   Wikidata; Q54955260
RX   PubMed=8824565;
RX   PubMed=11819450;
RX   PubMed=19956504;
RX   PubMed=31063779;
RX   PubMed=31378681;
WW   https://lccl.zucmanlab.com/hcc/cellLines/SNU739
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: Liver Cancer Model Repository (LIMORE).
CC   Part of: Seoul National University (SNU) cell line collection.
CC   Population: Korean.
CC   Doubling time: 20 hours (PubMed=11819450); 24.99 hours (PubMed=31378681).
CC   Sequence variation: Mutation; HGNC; 18040; ARID1B; Simple; p.Gln149Serfs*83 (c.444dupT); Zygosity=Unspecified (PubMed=31378681).
CC   Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Arg3384Ter (c.10150C>T); ClinVar=VCV000051049; Zygosity=Homozygous (DepMap).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31378681).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Arg (c.645T>G); ClinVar=VCV000376661; Zygosity=Unspecified (PubMed=8824565; PubMed=31378681; DepMap).
CC   Transformant: NCBI_TaxID; 10407; Hepatitis B virus (HBV).
CC   Omics: Deep exome analysis.
CC   Omics: Genome sequenced.
CC   Omics: miRNA expression profiling.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
ST   Source(s): KCLB; PubMed=31378681
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 8
ST   D16S539: 9,12
ST   D3S1358: 15,17
ST   D5S818: 11,12
ST   D7S820: 9,11
ST   FGA: 24
ST   TH01: 7,9
ST   TPOX: 8,9
ST   vWA: 17
DI   NCIt; C7956; Adult hepatocellular carcinoma
DI   ORDO; Orphanet_210159; Adult hepatocellular carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   52Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 21
//
RX   PubMed=8824565; DOI=10.1002/(SICI)1097-0215(19960917)67:6<898::AID-IJC22>3.0.CO;2-X;
RA   Kang M.-S., Lee H.-J., Lee J.-H., Ku J.-L., Lee K.P., Kelley M.J.,
RA   Won Y.-J., Kim S.-T., Park J.-G.;
RT   "Mutation of p53 gene in hepatocellular carcinoma cell lines with HBX
RT   DNA.";
RL   Int. J. Cancer 67:898-902(1996).
//
RX   PubMed=11819450; DOI=10.3748/wjg.v5.i4.289;
RA   Lee J.-H., Ku J.-L., Park Y.-J., Lee K.-U., Kim W.-H., Park J.-G.;
RT   "Establishment and characterization of four human hepatocellular
RT   carcinoma cell lines containing hepatitis B virus DNA.";
RL   World J. Gastroenterol. 5:289-295(1999).
//
RX   PubMed=19956504; DOI=10.4143/crt.2005.37.1.1;
RA   Ku J.-L., Park J.-G.;
RT   "Biology of SNU cell lines.";
RL   Cancer Res. Treat. 37:1-19(2005).
//
RX   PubMed=31063779; DOI=10.1053/j.gastro.2019.05.001;
RA   Caruso S., Calatayud A.-L., Pilet J., La Bella T., Rekik S.,
RA   Imbeaud S., Letouze E., Meunier L., Bayard Q., Rohr-Udilova N.,
RA   Peneau C., Grasl-Kraupp B., de Koning L., Ouine B., Bioulac-Sage P.,
RA   Couchy G., Calderaro J., Nault J.-C., Zucman-Rossi J., Rebouissou S.;
RT   "Analysis of liver cancer cell lines identifies agents with likely
RT   efficacy against hepatocellular carcinoma and markers of response.";
RL   Gastroenterology 157:760-776(2019).
//
RX   PubMed=31378681; DOI=10.1016/j.ccell.2019.07.001;
RA   Qiu Z.-X., Li H., Zhang Z.-T., Zhu Z.-F., He S., Wang X.-J.,
RA   Wang P.-C., Qin J.-J., Zhuang L.-P., Wang W., Xie F.-B., Gu Y.,
RA   Zou K.-K., Li C., Li C., Wang C.-H., Cen J., Chen X.-T., Shu Y.-J.,
RA   Zhang Z., Sun L.-L., Min L.-H., Fu Y., Huang X.-W., Lv H., Zhou H.,
RA   Ji Y., Zhang Z.-G., Meng Z.-Q., Shi X.-L., Zhang H.-B., Li Y.-X.,
RA   Hui L.-J.;
RT   "A pharmacogenomic landscape in human liver cancers.";
RL   Cancer Cell 36:179-193.e11(2019).
//